LeonaBio, Inc. is a clinical-stage biopharmaceutical company developing small-molecule therapeutics designed to restore neuronal health and slow neurodegenerative processes. The company's pipeline consists of two lead candidates currently in Phase 1 clinical trials: ATH-1105 for amyotrophic lateral sclerosis (ALS) and ATH-1020 for broader neurodegenerative disease indications. The company also maintains early-stage compounds in preclinical development. LeonaBio was formerly known as Athira Pharma, Inc. until rebranding in January 2026.
Incorporated in 2011, the company operates as a clinical-stage entity with no disclosed revenue streams, consistent with its development status prior to potential regulatory approvals. The organization is headquartered in Bothell, Washington, and maintains a small operational footprint with 26 full-time employees. As a Nasdaq-listed company, LeonaBio is dependent on capital markets funding to support its clinical development programs and ongoing operations.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2024 | $-2.52 | $-2.52 | +18.4% | |
| 2023 | $-3.09 | $-3.09 | -22.1% | |
| 2022 | $-2.53 | $-2.53 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |